Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms – Cytokinetics

1. Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms  Cytokinetics
2. US FDA approves Cytokinetics’ heart disease drug  TradingView — Track All Markets
3. Cytokinetics’ Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy?  BioSpace
4. Cytokinetics’ Hypertrophic Cardiomyopathy Treatment Approved in China  marketscreener.com
5. Cytokinetics awaits FDA decision that could unlock billions in drug sales for heart failure treatment  The Business Journals

Continue Reading